35 related articles for article (PubMed ID: 11186135)
1. Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank.
Fisher MB; Vandenbranden M; Findlay K; Burchell B; Thummel KE; Hall SD; Wrighton SA
Pharmacogenetics; 2000 Nov; 10(8):727-39. PubMed ID: 11186135
[TBL] [Abstract][Full Text] [Related]
2. Evidence for regulation of UDP-glucuronosyltransferase (UGT) 1A1 protein expression and activity via DNA methylation in healthy human livers.
Yasar U; Greenblatt DJ; Guillemette C; Court MH
J Pharm Pharmacol; 2013 Jun; 65(6):874-83. PubMed ID: 23647681
[TBL] [Abstract][Full Text] [Related]
3. UDP-glucuronosyltransferases and clinical drug-drug interactions.
Kiang TK; Ensom MH; Chang TK
Pharmacol Ther; 2005 Apr; 106(1):97-132. PubMed ID: 15781124
[TBL] [Abstract][Full Text] [Related]
4. Racial Disparity in Drug Disposition in the Digestive Tract.
Gao S; Bell EC; Zhang Y; Liang D
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33494365
[TBL] [Abstract][Full Text] [Related]
5. Contributions of Hepatic and Intestinal Metabolism to the Disposition of Niclosamide, a Repurposed Drug with Poor Bioavailability.
Fan X; Li H; Ding X; Zhang QY
Drug Metab Dispos; 2019 Jul; 47(7):756-763. PubMed ID: 31040114
[TBL] [Abstract][Full Text] [Related]
6. Interindividual variation in gene expression responses and metabolite formation in acetaminophen-exposed primary human hepatocytes.
Jetten MJ; Ruiz-Aracama A; Coonen ML; Claessen SM; van Herwijnen MH; Lommen A; van Delft JH; Peijnenburg AA; Kleinjans JC
Arch Toxicol; 2016 May; 90(5):1103-15. PubMed ID: 26104854
[TBL] [Abstract][Full Text] [Related]
7. Comparing the metabolism of quercetin in rats, mice and gerbils.
Yeh SL; Lin YC; Lin YL; Li CC; Chuang CH
Eur J Nutr; 2016 Feb; 55(1):413-22. PubMed ID: 25691233
[TBL] [Abstract][Full Text] [Related]
8. A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.
Frechen S; Junge L; Saari TI; Suleiman AA; Rokitta D; Neuvonen PJ; Olkkola KT; Fuhr U
Clin Pharmacokinet; 2013 Sep; 52(9):763-81. PubMed ID: 23653047
[TBL] [Abstract][Full Text] [Related]
9. Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).
Knights KM; Rowland A; Miners JO
Br J Clin Pharmacol; 2013 Oct; 76(4):587-602. PubMed ID: 23362865
[TBL] [Abstract][Full Text] [Related]
10. Influence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients.
Singkham N; Towanabut S; Lertkachatarn S; Punyawudho B
Eur J Clin Pharmacol; 2013 Jun; 69(6):1285-91. PubMed ID: 23263737
[TBL] [Abstract][Full Text] [Related]
11. The biochemistry of acetaminophen hepatotoxicity and rescue: a mathematical model.
Ben-Shachar R; Chen Y; Luo S; Hartman C; Reed M; Nijhout HF
Theor Biol Med Model; 2012 Dec; 9():55. PubMed ID: 23249634
[TBL] [Abstract][Full Text] [Related]
12. Analysis of estrogens in serum and plasma from postmenopausal women: past present, and future.
Blair IA
Steroids; 2010 Apr; 75(4-5):297-306. PubMed ID: 20109478
[TBL] [Abstract][Full Text] [Related]
13. Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates.
Harper TW; Brassil PJ
AAPS J; 2008; 10(1):200-7. PubMed ID: 18446520
[TBL] [Abstract][Full Text] [Related]
14. Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes.
Peterkin VC; Bauman JN; Goosen TC; Menning L; Man MZ; Paulauskis JD; Williams JA; Myrand SP
Br J Clin Pharmacol; 2007 Oct; 64(4):458-68. PubMed ID: 17555467
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms in human SULT1A1 and UGT1A1 genes associate with breast tumor characteristics: a case-series study.
Shatalova EG; Walther SE; Favorova OO; Rebbeck TR; Blanchard RL
Breast Cancer Res; 2005; 7(6):R909-21. PubMed ID: 16280036
[TBL] [Abstract][Full Text] [Related]
16. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception.
Zelcer N; van de Wetering K; Hillebrand M; Sarton E; Kuil A; Wielinga PR; Tephly T; Dahan A; Beijnen JH; Borst P
Proc Natl Acad Sci U S A; 2005 May; 102(20):7274-9. PubMed ID: 15886284
[TBL] [Abstract][Full Text] [Related]
17. Morphine pharmacokinetics during venoarterial extracorporeal membrane oxygenation in neonates.
Peters JW; Anderson BJ; Simons SH; Uges DR; Tibboel D
Intensive Care Med; 2005 Feb; 31(2):257-63. PubMed ID: 15678314
[TBL] [Abstract][Full Text] [Related]
18. Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: an overview.
Guillemette C; Bélanger A; Lépine J
Breast Cancer Res; 2004; 6(6):246-54. PubMed ID: 15535854
[TBL] [Abstract][Full Text] [Related]
19. Mapping of a quantitative trait locus for morphine withdrawal severity.
Kest B; Palmese CA; Juni A; Chesler EJ; Mogil JS
Mamm Genome; 2004 Aug; 15(8):610-7. PubMed ID: 15457340
[TBL] [Abstract][Full Text] [Related]
20. Farnesol is glucuronidated in human liver, kidney and intestine in vitro, and is a novel substrate for UGT2B7 and UGT1A1.
Staines AG; Sindelar P; Coughtrie MW; Burchell B
Biochem J; 2004 Dec; 384(Pt 3):637-45. PubMed ID: 15320866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
